Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled Trial
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
Immunoglobulin A (IgA) nephropathy is the most common type of primary glomerulonephritis in
the world. The treatment of IgA nephropathy with normal renal function and minimal
proteinuria is unknown. Since angiotensin-converting enzyme (ACE) inhibitors reduce
proteinuria and retard the rate of decline of renal function in chronic proteinuric
nephropathies, including IgA nephropathy. The investigators conduct a randomized control
study to evaluate the efficacy of ACE inhibitor in the treatment of early IgA nephropathy.
Sixty patients with biopsy-proven IgA nephropathy and minimal proteinuria are recruited. They
will be randomized to ramipril for 5 years or no treatment. Blood pressure, proteinuria and
renal function will be monitored. This study will explore the effects of ACE inhibitor in the
treatment of early IgA nephropathy, which is a major cause of dialysis-dependent renal
failure.
Phase:
Phase 3
Details
Lead Sponsor:
Chinese University of Hong Kong
Treatments:
Angiotensin-Converting Enzyme Inhibitors Antibodies Enzyme Inhibitors Immunoglobulin A Immunoglobulins Ramipril